問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Internal Medicine

更新時間：2023-09-19

馮博皓Feng, Po-Hao
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 10 個月

Recruiting Trial

63Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

馮博皓

List

100Cases

2014-09-01 - 2018-11-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2022-08-25 - 2025-12-19

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2024-02-06 - 2029-08-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2017-02-10 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Recruiting13Sites

夏德椿
China Medical University Hospital-Taipei

未分科

張家崙
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Hematology & Oncology

2024-08-01 - 2028-11-05

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-06-01 - 2030-05-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-07-01 - 2030-06-30

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-05-01 - 2029-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting10Sites

Recruiting1Sites

2022-03-01 - 2026-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2022-02-28 - 2026-12-10

Phase I/II

Active
An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

  • Condition/Disease

    Advanced Non-small Cell Lung Cancer、EGFR Mutation、HER2 Mutation

  • Test Drug

    BAY 2927088

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting2Sites

Terminated3Sites

1 5 6 7 8 9 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB